In HER2-positive breast cancer patients undergoing anthracycline and trastuzumab therapy, the use of lisinopril or carvedilol as cardioprotective agents may help reduce the risk of the trastuzumab discontinuation due to cardiotoxicity [132]. The gene discussed is ERBB2; the disease is breast cancer.